Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reviewed evidence on eribulin's efficacy and safety for treating metastatic triple-negative breast cancer, highlighting variable survival outcomes and manageable safety profiles for both monotherapy and combination therapies.

This study observed that in a real-world clinical setting in Greece, belimumab effectively controlled disease activity in lupus patients and allowed for a reduction in glucocorticoid dosage, with more pronounced benefits seen in patients who were serologically active at the start of treatment.

In this study, GTx-027, a selective androgen receptor modulator, significantly inhibited tumor growth in certain breast cancer models and showed good tolerance in a Phase II trial with postmenopausal women.

In a preclinical mouse model, this study found that early treatment with the selective SYK inhibitor entospletinib significantly improved survival rates and clinical outcomes for graft-versus-host disease after hematopoietic stem cell transplantation compared to placebo.

This study found that GTx-024 significantly increased total lean body mass and improved physical function in healthy elderly men and postmenopausal women, suggesting potential use for muscle wasting conditions.

In this study, the choice between Belimumab and Anifrolumab for treating Systemic Lupus Erythematosus was mainly influenced by the clinical features of the disease, such as chronic-active or relapsing-remitting courses and specific manifestations like cutaneous involvement or arthritis.

This study found that oral paclitaxel combined with encequidar improved tumor response rates compared to intravenous paclitaxel in women with metastatic breast cancer, while also reducing neuropathy but increasing certain gastrointestinal and neutropenic side effects.

This study observed that the choice between using Belimumab and Anifrolumab for treating active Systemic Lupus Erythematosus was mainly based on clinical phenotype, with Anifrolumab linked to chronic-active disease and Belimumab associated with relapsing-remitting disease.

This study reported that while general patient characteristics and adverse event incidence for eribulin were comparable between a healthcare claims database and post-marketing surveillance, significant differences in some side effects such as neutropenia were observed.

This study found that belimumab helped achieve low disease activity in over 40% of systemic lupus erythematosus patients in real-life settings, alongside reduced corticosteroid use and fewer flares.

In this multicenter study, belimumab effectively reduced disease activity in systemic lupus erythematosus patients with joint and skin manifestations, showing significant improvement in acute and subacute skin types earlier than in chronic types, while no significant benefit was observed for nonspecific skin manifestations.

In this study, encorafenib combined with binimetinib was well tolerated in melanoma patients, resulting in relatively few cutaneous adverse events compared to other BRAF and MEK inhibitors.

This article discusses the development and clinical progress of PROTAC technology, particularly focusing on the New Drug Application for vepdegestrant, an estrogen receptor-targeting PROTAC, marking significant advancements in targeted protein degradation therapies.

This study identified common and previously unlisted adverse events associated with four anti-CGRP monoclonal antibodies for migraine prevention, highlighting a varied safety profile post-marketing.

This paper discusses a case of acrodermatitis continua that was resistant to treatment with etanercept, highlighting the therapeutic challenges faced, but reports no new research results.

This review discusses common skin eruptions caused by biologics in treating inflammatory bowel disease and proposes tailored therapeutic approaches for managing these adverse reactions.

This study examined the market trends for biologics that have lost patent exclusivity and predicted that drugs like adalimumab, once facing competition, could see price reductions and decreased market share, although the impact on accessibility and total patient use remains unclear.

This review discusses several new pharmacological products, including those for cardiovascular prevention and overactive bladder, but notes challenges in defining their therapeutic roles and provides safety updates on existing medications; it reports no new clinical results.

This study reported that belimumab helped over 40% of active systemic lupus erythematosus patients achieve low disease activity, with more than 20% able to stop glucocorticoids completely.

This review outlines the various adverse reactions to biologic therapies in Allergy/Immunology, emphasizing the clinical and management challenges due to overlapping reaction phenotypes and the need for more refined diagnostic and management strategies.

This case report describes a 40-year-old woman who developed erythema annulare centrifugum, a type of skin rash, likely triggered by taking the drug aceclofenac.

This study found that both Elental and 6-mercaptopurine were effective for maintaining remission in Crohn's disease, without a significant difference between them over 24 months.

This document provides a legal disclaimer and offers no research findings.

In this study, 93% of patients with inflammatory arthritis remained on the adalimumab biosimilar ABP 501 for 24 weeks after switching from the originator, with some switching back due to adverse reactions or reduced effectiveness.

This phase II trial found that BI 2536 demonstrated limited antitumor activity across five solid tumor types, with no confirmed objective responses observed.

In this case report, two patients with coexisting systemic lupus erythematous and neuromyelitis optica spectrum disorder achieved remission of SLE activity using an anti-CD19 monoclonal antibody.

This article discusses the discontinuation of the Bexxar regimen for non-Hodgkin's lymphoma, noting that despite its effectiveness, it was under-prescribed due to marketing and development challenges without reporting new clinical results.

This study found that engineered high-affinity soluble CD200R agonists, including ARQ-234, showed superior efficacy in reducing immune responses in various preclinical models of inflammatory conditions, suggesting potential as a therapeutic for atopic dermatitis and other related diseases.